100Xfounder
Get Featured

BillionToOne is a precision diagnostics company that makes molecular diagnostics. Healthcare Medical Biotech

About BillionToOne

The Problem Healthcare teams often struggle with fragmented workflows, slow decision cycles, and unclear accountability when they try to solve important operating problems with generic tools. For BillionToOne, the core problem is turning that category pressure into a focused product motion for customers operating in or around San Francisco Bay Area, California, USA.

The Solution BillionToOne's profile describes the company as "BillionToOne is a precision diagnostics company that makes molecular diagnostics. Healthcare Medical Biotech". The practical solution angle is a focused layer for healthcare teams: reduce manual coordination, improve decision visibility, and give customers a clearer way to act on the workflow that the company has chosen to own.

Buyer Context BillionToOne's buyer context starts with care teams, administrators, life-science operators, and patient-experience leaders. In Healthcare, those readers usually care about safety, accuracy, compliance, workflow continuity, and measurable service improvement. The practical question is whether "BillionToOne is a precision diagnostics company that makes molecular diagnostics. Healthcare Medical Biotech" can translate into better coordination, clearer clinical or operational insight, and reduced friction for users for customers operating in or around San Francisco Bay Area, California, USA.

Market Timing Healthcare is being shaped by digitized healthcare workflows, preventive analytics, and patient-first digital journeys. That timing matters for BillionToOne because series C execution usually means the company is scaling teams, expanding customer segments, and tightening operating discipline. The profile is most useful when readers connect that stage context with the realities of building from San Francisco Bay Area, California, USA.

Operating Signals Team size is listed as 201-500 employees, pointing to a scaled operating footprint. Funding context is Y Combinator, $125M Series C in 2022. Hiring is active, with visible role focus in Open Roles. Read together, these signals help explain whether BillionToOne is still validating a focused wedge, scaling a repeatable motion, or preparing for broader strategic milestones.

Comparison Lens BillionToOne is best compared with companies sharing Healthcare and Series C signals. Against that peer set, look at product specificity, stage maturity, geographic operating base, funding context, and whether hiring points toward product, sales, operations, or customer delivery.

Research Checklist

  • Map the customer segment behind "BillionToOne is a precision diagnostics company that makes molecular diagnostics. Healthcare Medical Biotech" to the core workflow pressure inside Healthcare.
  • Compare Series C progress with companies operating from San Francisco Bay Area, California, USA and adjacent Healthcare categories.
  • Read the funding context alongside team size to judge whether resources match the stated market opportunity.
  • Use role focus in Open Roles to infer where the company is investing next.
  • Review connected founder, funding, news, and peer-company pages before making a partnership, hiring, or market-mapping decision.

What to Watch Next BillionToOne's next useful signals are how funding context turns into sharper product depth, stronger distribution, or new market coverage, whether hiring in Open Roles becomes visible in product, sales, operations, or customer delivery, and whether BillionToOne deepens its position in Healthcare beyond the current profile snapshot.

Culture The available profile points to a culture built around focused execution: product clarity from the healthcare category, customer awareness from the one-liner, and disciplined prioritization from the company's stage, team size, funding context, and hiring signals.

Why it Matters

BillionToOne matters now because billionToOne has a stronger timing story when viewed against digitized healthcare workflows, preventive analytics, and patient-first digital journeys. The company's opportunity depends on turning category urgency into repeatable adoption, durable customer proof, and a sharper operating model. Team size is listed as 201-500 employees, pointing to a scaled operating footprint. Funding context is Y Combinator, $125M Series C in 2022. Hiring is active, with visible role focus in Open Roles. Read together, these signals help explain whether BillionToOne is still validating a focused wedge, scaling a repeatable motion, or preparing for broader strategic milestones.

Market Context for BillionToOne

BillionToOne sits inside the Healthcare market, where buyers usually compare vendors on speed, trust, implementation depth, and the ability to show measurable outcomes. The company's current profile points to Series C stage execution, a primary operating base around San Francisco Bay Area, California, USA, and a funding signal of $125.00M. Those details help readers separate a basic company listing from a stronger operating brief.

For founders and operators, the useful question is not only what BillionToOne sells, but whether the company is building repeatable go-to-market motion in its category. The product summary, founder footprint, hiring status, and Series C at Y Combinator, $125M Series C in 2022 give a practical way to read momentum. If the company is hiring, it may signal new customer demand, product expansion, or regional growth. If hiring is quiet, readers can still compare product focus, funding history, and peer activity before drawing conclusions.

Use this page as a research starting point for the company, then move into connected founder profiles, industry hubs, funding-stage pages, and related company comparisons. That route gives a clearer picture of where BillionToOne fits in the market and which adjacent companies are moving in the same direction.

Category Lens

Compare BillionToOne with other Healthcare companies to understand peer density, buyer demand, and market maturity.

Funding Lens

Track Series C signals, total funding, and round history to judge whether the company is still proving demand or scaling execution.

People Lens

Founder background, open roles, and team size show how the company is investing in product, sales, operations, and customer delivery.

Funding Snapshot

Total Funding: $125.00MLast Round: Series C Y Combinator, $125M Series C in 2022All Rounds: 1
  • Series CY Combinator, $125M Series C in 2022

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

Tech Stack

PythonGCPBigQueryReact

Last updated: February 23, 2026

BillionToOne intelligence brief

This profile combines core company context with linked founder, funding, and newsroom routes so readers can evaluate business momentum without switching across multiple tools. Use it as a baseline for comparing peers in the same industry and stage.

For deeper validation, pair this page with founder profile, company news coverage, and stage-based funding hubs to contextualize updates against wider market movement.

The highest-signal way to use this page is to read it as a company brief, not just a static directory listing. Look at how the product summary, funding context, hiring activity, and founder footprint fit together. When these signals align, the page becomes more useful for investors, operators, and founder-research workflows than a basic profile card or shallow company database entry.

Related Companies

Alternatives in Healthcare with comparable market signals.

Discover Now

Newsroom and topic pages connected to BillionToOne.

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

FAQs About BillionToOne

Common questions people ask about this profile.

What is BillionToOne?

BillionToOne is a precision diagnostics company that makes molecular diagnostics. Healthcare Medical Biotech

Who founded BillionToOne?

BillionToOne is associated with BillionToOne Team on 100Xfounder.

Where is BillionToOne located?

BillionToOne is listed in San Francisco Bay Area, California, USA.

What stage is BillionToOne in?

BillionToOne is currently mapped to Series C. Funding context: Y Combinator, $125M Series C in 2022

What is the latest funding round of BillionToOne?

BillionToOne's latest tracked round is Series C Y Combinator, $125M Series C in 2022. Total tracked rounds: 1.

Is BillionToOne hiring now?

BillionToOne hiring status: Open Roles.

What technologies does BillionToOne use?

BillionToOne is associated with Python, GCP, BigQuery, and React.

Is BillionToOne verified on 100Xfounder?

Yes. BillionToOne is currently marked verified on 100Xfounder as of July 23, 2026.

How can users connect with BillionToOne founders?

Users can open founder profiles, use listed company links, and track signal updates directly from the 100Xfounder directory.